Precision-oncology biotech using synthetic-lethality targets; lead drug darovasertib treats uveal melanoma.
Precision-oncology biotech using synthetic-lethality targets; lead drug darovasertib treats uveal melanoma.
Has no approved product, so revenue is limited to payments from partners such as GSK, which works with it on its Pol theta programme; trials are funded by cash raised from selling shares. Darovasertib is a pill that blocks a protein driving uveal melanoma, a rare eye cancer.
Moat: none (IP / patents). Clinical-stage biotech; value depends on trial data and partner (GSK) milestone payments.
Headquarters: South San Francisco, California, US · Founded: 2015 · Employees: 145
Size IDEAYA Biosciences (IDYA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $2.56B, the 1630th largest of 3,085 United States companies the cockpit tracks. Shares closed at $26.49 on 18 Nov 2026.
Performance Over six months the shares fell 10.7%, against -8.4% for the median peer and -2.2% for the United States market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue fell 83.0% over the last twelve months (peer median +5.1%); the operating margin is -1,267.4% (peer median 11.3%).
Valuation It trades at 48.0× enterprise value to sales against a peer median of 4.2× (2nd most expensive of 20).
Capital Return on invested capital runs 135.7 points below its cost of capital (6.6% WACC).
Backlog Backlog (remaining performance obligations) was $140M at 30 Sep 2026, down 2% on a year earlier. Backlog detail →
Short interest Short interest is 8.5% of the free float (30 Oct 2026).
Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $36.5M | $219M | $7.00M | $23.4M | $50.9M |
| Revenue growth | — | +3,024% | -70% | -54% | — |
| Gross profit | $32.0M | $214M | $3.17M | $19.4M | $48.8M |
| EBITDA | -$459M | -$155M | -$323M | -$130M | -$60.4M |
| Net income | -$420M | -$114M | -$274M | -$113M | -$58.7M |
| Free cash flow | -$350M | -$73.5M | -$251M | -$118M | -$90.6M |
| Capital expenditure | $2.44M | $2.37M | $3.86M | $2.37M | $3.44M |
| Total debt | $29.7M | $27.9M | $19.2M | $2.87M | $3.48M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| IDEAYA Biosciences IDYA | $2.56B | -11% | -83% | -1,267% | 48.0× | n/a |
| GSK GSK.L | $97.9B | -3% | +4% | 25% | 2.8× | -0.1% |
| Foghorn Therapeutics FHTX | n/a | -55% | n/a | n/a | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | $1.44B | -7% | +13% | -7% | 2.3× | n/a |
| Tango Therapeutics TNGX | $3.71B | +4% | -100% | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IDYA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -25.1% | -3.6% | 3rd lowest of 21 |
| 6-month return | -10.7% | -8.4% | 10th lowest of 21 |
| Distance from 52-week high | -37.9% | -27.5% | 10th lowest of 21 |
| Revenue growth (TTM) | -83.0% | +5.1% | lowest of 20 |
| Operating margin | -1,267.4% | 11.3% | lowest of 20 |
| EV / Sales | 48.0× | 4.2× | 2nd most expensive of 20 |
| ROIC minus cost of capital | -135.7 pp | -1.2 pp | lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| IDEAYA Biosciences IDYA | United States | $2.56B | -11% | -83% | -1,267% | 48.0× | n/a | n/a |
| Kangmei Pharmaceutical 600518.SS | China | $2.61B | -21% | -6% | -7% | 3.3× | n/a | n/a |
| Yili Chuanning Biotechnology 301301.SZ | China | $2.49B | -24% | -14% | 16% | 4.2× | 3.4% | +4.8% |
| BioArctic BIOA-B.ST | Sweden | $2.66B | -9% | -46% | 22% | 25.1× | 25.5% | +100.1% |
| Almirall ALM.MC | Spain | $2.46B | -13% | +24% | 8% | 1.9× | 6.1% | +6.5% |
| Hybio Pharmaceutical 300199.SZ | China | $2.68B | -8% | +70% | 31% | 12.9× | 37.4% | +6.1% |
| Betta Pharmaceuticals 300558.SZ | China | $2.70B | -15% | +16% | 11% | 5.2× | 23.2% | +14.0% |
| Prestige Consumer Healthcare PBH | United States | $2.40B | +7% | +5% | 25% | 3.8× | 2.3% | +2.9% |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.40B | -33% | +153% | -7% | 13.6× | 37.9% | +22.9% |
| Keymed Biosciences 2162.HK | Hong Kong | $2.39B | +7% | 0% | -73% | 16.8× | n/a | n/a |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.38B | +14% | -9% | -6% | 2.0× | 47.0% | +19.3% |
| NewAmsterdam Pharma NAMS | United States | $2.37B | -45% | -26% | -900% | 67.0× | n/a | n/a |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.36B | -66% | +23% | 7% | 11.8× | n/a | n/a |
| Perrigo PRGO | United States | $2.35B | +52% | -4% | 5% | 1.3× | 14.1% | +0.8% |
| Regencell Bioscience RGC | United States | $2.33B | -83% | n/a | n/a | n/a | n/a | n/a |
| Acrobiosystems 301080.SZ | China | $2.31B | +65% | +29% | 17% | 14.0× | 41.3% | +27.7% |
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.85B | 0% | -12% | 18% | 1.6× | -13.1% | +2.4% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.25B | -7% | +4% | 10% | 1.5× | -2.5% | -5.8% |
| Neuland Laboratories NEULANDLAB.NS | India | $2.95B | +28% | +50% | 26% | 11.9× | n/a | n/a |
| China Medical System 0867.HK | Hong Kong | $2.95B | -15% | +15% | 20% | 1.8× | 1.1% | +2.7% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.20B | +39% | +20% | 12% | 2.6× | 26.7% | +6.5% |
IDEAYA Biosciences reported $140M of remaining performance obligations at 30 Sep 2026, down 2% from a year earlier and down 5% from the previous quarter. Book-to-bill last quarter: 0.29.